Telomir Pharmaceuticals, Inc. Common StockTELONASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -0.24% | +1.66% | +1.35% | +4.83% | +16.39% |
| Weighted Average Shares Diluted Growth | -0.24% | +1.66% | +1.35% | +4.83% | +16.39% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | +0.00% | -100.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -72.26% | -85.98% | -60.53% | +610.39% | +454.48% |
| Book Value per Share Growth | -81.25% | +0.00% | -69.71% | +1406.02% | +690.10% |
| Debt Growth | -7.49% | +1082.38% | +0.00% | +0.00% | -100.00% |
| R&D Expense Growth | +32.04% | -58.09% | -92.80% | +21.05% | +381.71% |
| SG&A Expenses Growth | +201.35% | +149.59% | +471.46% | -92.81% | -68.20% |